Brentuximab vedotin. an antibody-drug conjugate targeting CD30

DOI Web Site Web Site 18 References
  • Yanai Tomoko
    Global Medical Affairs-Japan, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited

Bibliographic Information

Other Title
  • CD30を標的とする抗体薬物複合体Brentuximab vedotin
  • CD30 オ ヒョウテキ ト スル コウタイ ヤクブツ フクゴウタイ Brentuximab vedotin

Search this article

Description

Brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30, is indicated for the treatment of CD30-positive relapsed/refractory Hodgkin’s lymphoma and anaplastic large cell lymphoma. When BV is internalized by CD30-positive cells, MMAE binds to microtubules to induce apoptosis. Clinically significant adverse reactions to BV include peripheral nerve disorder, infection, bone marrow suppression, and infusion reaction. The efficacy and safety of BV used in combination with other antitumor drugs have not been established. The results of multinational Phase III clinical studies of BV with chemotherapy in untreated HL and untreated CD30-positive mature T-cell lymphoma are anticipated.

Journal

  • Drug Delivery System

    Drug Delivery System 32 (2), 126-133, 2017

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(18)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top